论文信息 - Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study - 字舞流文

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

L. Coates | D. Gladman | V. Strand | A. Kavanaugh | L. Gossec | O. FitzGerald | S. Jugl | P. Nash | T. Kvien | L. Rasouliyan | C. Gaillez | L. Pricop | K. Ding | O. B. O. T. F. 2. S. group